These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 594790)

  • 41. Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate.
    Maatman TJ; Gupta MK; Montie JE
    J Urol; 1985 Apr; 133(4):620-1. PubMed ID: 3981712
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chemo-endocrine therapy in patients with stage D2 prostate cancer.
    Kubota Y; Nakada T; Imai K; Yamanaka H; Sakai H; Saito Y; Tomaru Y; Kitamura K; Sugano O; Sasagawa I
    Prostate; 1995 Jan; 26(1):50-4. PubMed ID: 7845867
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate.
    Gibbons RP; Beckley S; Brady MF; Chu TM; Dekernion JB; Dhabuwala C; Gaeta JF; Loening SA; McKiel CF; McLeod DG; Pontes JE; Prout GR; Scardino PT; Schlegel JU; Schmidt JD; Scott WW; Slack NH; Soloway MS; Murphy GP
    J Surg Oncol; 1983 Jun; 23(2):133-42. PubMed ID: 6343726
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Experience with low-dose oestrogen in the treatment of advanced prostate cancer: a personal view.
    Bishop MC
    Br J Urol; 1996 Dec; 78(6):921-7; discussion 927-8. PubMed ID: 9014720
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early combined hormonal and chemotherapy for metastatic prostatic carcinoma.
    Servadio C; Mukamel E; Lurie H; Nissenkorn I
    Urology; 1983 May; 21(5):493-5. PubMed ID: 6857889
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel treatments for castration-resistant prostate cancer.
    Sternberg CN
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S195-9. PubMed ID: 21943975
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of castration-induced menopausal symptoms with low dose diethylstilbestrol in men with advanced prostate cancer.
    Miller JI; Ahmann FR
    Urology; 1992 Dec; 40(6):499-502. PubMed ID: 1281587
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Response of serum cholesterol and triglycerides to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer.
    Seal US; Doe RP; Byar DP; Corle DK
    Cancer; 1976 Sep; 38(3):1095-107. PubMed ID: 182347
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment of prostatic neoplasms; is hormone therapy more effective than orchiectomy?].
    Med Welt; 1979 Nov; 30(46):1711-4. PubMed ID: 537494
    [No Abstract]   [Full Text] [Related]  

  • 50. Combined external radiotherapy and hormonal therapy for localized carcinoma of the prostate.
    Mukamel E; Servadio C; Lurie H
    Prostate; 1983; 4(3):283-7. PubMed ID: 6844159
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy.
    Geller J; Albert JD; Nachtsheim DA; Loza D
    J Urol; 1984 Oct; 132(4):693-6. PubMed ID: 6471215
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Carcinoma of the prostate in Israel: some epidemiological and therapeutic considerations.
    Servadio C; Mukamel E; Kahan E
    Prostate; 1984; 5(4):375-82. PubMed ID: 6739372
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Chemoendocrine therapy of newly diagnosed advanced prostatic cancer].
    Numasawa K; Kubota Y; Suzuki H; Kakizaki H; Takamizawa A; Saito M; Suzuki K; Kato H; Hirano J; Hirano K
    Nihon Hinyokika Gakkai Zasshi; 1989 Jan; 80(1):39-47. PubMed ID: 2724744
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.
    Huggins C; Hodges CV
    J Urol; 2002 Jul; 168(1):9-12. PubMed ID: 12050481
    [No Abstract]   [Full Text] [Related]  

  • 55. Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population.
    Aro J
    Prostate; 1991; 18(2):131-7. PubMed ID: 2006119
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of castration and di-ethyl stilboestrol in a patient with myelophthisic anemia secondary to carcinoma of the prostate.
    COMMONS RR; STRAUSS MB
    J Clin Invest; 1947 Nov; 26(6):1178. PubMed ID: 20272558
    [No Abstract]   [Full Text] [Related]  

  • 57. A comparative follow-up study of the therapeutic value of bilateral orchiectomy in the treatment of carcinoma of the prostate gland.
    SCOTT WW; BENJAMIN JA
    J Urol; 1948 Oct; 60(4):604-11. PubMed ID: 18885948
    [No Abstract]   [Full Text] [Related]  

  • 58. Prevention of body fluid retention by furosemide during estrogen therapy of prostatic cancer.
    Kontturi MJ; Sotaniemi EA
    J Urol; 1975 Aug; 114(2):251-3. PubMed ID: 1159921
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined hormone-chemotherapy for metastatic prostatic carcinoma. Eleven-year follow-up.
    Servadio C; Savion M; Mukamel E
    Urology; 1987 Oct; 30(4):352-5. PubMed ID: 3660524
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effects of castration and stilboestrol on prostatic tumours in mice.
    HORNING ES
    Br J Cancer; 1949 Jun; 3(2):211-30. PubMed ID: 18132112
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.